Insulet Corp
PODD: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$673.00 | Gjsdgz | Fllnnlwx |
Insulet to Benefit From Further Integration With New Continuous Glucose Monitors
Business Strategy and Outlook
With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm is on the path to meaningful profitability gains.